Products

Main Indication:

MAREVAN is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. MAREVAN is indicated for the prophylaxis andor treatment of the thromboembolic complications associated with atrial fibrillation. MAREVAN is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (TIA, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. MAREVAN is indicated for use as an adjunct in the treatment of coronary occlusion.

Main Indication:

Palliative treatment of recurrent inoperable or metastatic carcinoma of the breast (see DOSAGE). It should not be used in lieu of currently accepted procedures such as surgery, radiation or chemotherapy.

Main Indication:

Used to treat the symptoms of moderately severe to severe Alzheimer’s Disease (AD). AD can be described as a general decline in all areas of mental ability.

Main Indication:

Treatment of acute inflammatory large bowel disease; Maintenance therapy of Crohn's colitis and ulcerative colitis in patients sensitive to sulfasalazine.

Main Indication:

Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. Metex XR may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Main Indication:

Reduces inflammation (pain, swelling, redness and heat) which is one of the body's reactions to injury and reduces the body's reaction to infection. It is used for the treatment of one or more of the following conditions: • skin diseases • allergic reactions • inflammation of the eyes • respiratory diseases and certain respiratory infections • diseases of the gut (gastrointestinal tract) • multiple sclerosis • rheumatic disorders • diseases of the blood • treatment of certain glandular conditions and tumours of the immune system.

Main Indication:

Hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis.

Main Indication:

Active Paget's disease

Hypercalcaemia.

Main Indication:

Minocycline may be used for the treatment of infections caused by any of the following organisms provided that they have been shown by bacteriological testing to be susceptible to minocycline: Escherichia coli, Enterobacter aerogenes, Haemophilus influenzae, Klebsiella and Proteus. It may also be used in the treatment of infections due to Streptococcus pyogenes (group A ?- haemolytic) and Streptococcus faecalis but because a large proportion of these organisms is resistant to tetracyclines, minocycline should be used only if the organisms have been shown to be definitely sensitive. Tetracyclines, including minocycline, are not the drugs of choice in the treatment of staphylococcal infections. Minocycline may be considered for the treatment of such infections only if other suitable agents are not available and the organism has been shown to be sensitive to minocycline. Minocycline may be used in the treatment of tetracycline-resistant acne.

Main Indication:

Treatment of major depression including relapse prevention.

Main Indication:

MIVACRON is a highly selective, non-depolarising neuromuscular blocking agent with a fast recovery profile, and a short duration of action. MIVACRON is used as an adjunct to general anaesthesia to relax skeletal muscles and to facilitate tracheal intubation and mechanical ventilation. This formulation contains no antimicrobial preservative and is intended for single patient use.

Main Indication:

MODURETIC is indicated in the treatment of patients with

• - oedema of cardiac origin;
• - hepatic cirrhosis with ascites;
• - hypertension in whom potassium depletion might be anticipated.

MODURETIC, with its combination of amiloride HCl and hydrochlorothiazide, minimises the possibility of the development of excessive potassium loss in patients during vigorous diuresis for prolonged periods. MODURETIC, with its built-in potassium sparing agent, is especially indicated in those conditions where the positive effect on potassium balance is particularly important.

MODURETIC may be used alone, or as an adjunct to other antihypertensive drugs. Since it enhances the action of these agents, the dosage of these antihypertensive drugs may need to be reduced to avoid the risk of an excessive drop in blood pressure.

Main Indication:

Treatment of opioid responsive, chronic severe pain.

Main Indication:

MOVALIS is indicated for the symptomatic treatment of osteoarthritis and rheumatoid arthritis.

Main Indication:

MOVLIS is indicated for the symptomatic treatment of osteoarthritis

Main Indication:

Amoxycillin and clavulanic acid tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms- Urinary tract infections (uncomplicated and complicated). Lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. Upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. Skin and skin structure infections.

Main Indication:

Amoxycillin and clavulanic acid tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms- Urinary tract infections (uncomplicated and complicated). Lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. Upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. Skin and skin structure infections.

Main Indication:

Management of anxiety disorders or for the short-term relief of the symptoms ofanxiety. Anxiety associated with depression is also responsive to MURELAX therapy. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The physician should periodically reassess the usefulness of the drug for the individual patient. Alcoholics with acute tremulousness, confusional state or anxiety associated with alcohol withdrawal are responsive to therapy.

Main Indication:

Main Indication:

For the temporary relief of redness and drying due to minor eye irritation caused by dust, smoke, smog, sun glare, wearing contact lenses or swimming.

Main Indication:

Gently washing or cleansing the eye or for relieving mild eyestrain or soreness. Use to provide relief from discomfort associated with minor irritation, overwork or stress, glare, wind, dust, smoke and air pollution.

Main Indication:

Main Indication:

Gently washing or cleansing the eye or for relieving mild eyestrain or soreness. Use to provide relief from discomfort associated with minor irritation, overwork or stress, glare, wind, dust, smoke and air pollution.

Main Indication:

Used temporarily to relieve minor eye irritation, dryness and burning due to dust, smoke, smog, glare, wearing contact lenses, colds, allergies, swimming, reading, driving, television or close work.

Main Indication:

Relief of minor eye irritation and fast removal of redness caused by plant allergies (pollen), fatigue, swimming, colds, smog, wind and eye strain from reading, driving, television and close work.

Main Indication:

Oral Administration: MYAMBUTOL is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. It has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. It should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. Selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies. In patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs - MYAMBUTOL, isoniazid, rifampicin and streptomycin - for the first 2-4 months: for example, MYAMBUTOL plus isoniazid plus rifampicin or MYAMBUTOL plus isoniazid plus streptomycin then continuing with a two drug regimen such as MYAMBUTOL plus isoniazid or MYAMBUTOL plus rifampicin. In patients who have received previous antituberculosis therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. Consequently, in such retreatment cases MYAMBUTOL should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. Antituberculosis drugs used with MYAMBUTOL have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. Isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. Alternating drug regimens have also been utilised.

Main Indication:

Treatment of cutaneous mycotic infections caused by Candida sp.

Main Indication:

Treatment of candidal infections of the oral and perioral area including oral thrush, angular cheilitis, denture stomatitis and in other conditions of the mouth, throat and tongue complicated by overgrowth of Candida albicans.

Main Indication:

Treatment of chronic granulocytic leukaemia. It has been shown to be superior to splenic irradiation when judged by survival times, control of spleen size and maintenance of haemoglobin levels. Although not curative, busulfan reduces the total granulocyte mass, relieves disease symptoms and improves the clinical state of the patient. Busulfan is not useful once blast transformation has occurred.

Busulfan produces prolonged remission in polycythaemia vera. It is especially useful in cases 32 resistant to radiophosphorus ( P) and where there is marked thrombocytosis. Busulfan is useful in selected cases of essential thrombocythaemia and myelofibrosis.